Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Preclinical Imaging (In-VIVO) Market
The global preclinical imaging (in-vivo) market is projected to grow from USD 1,688.1 million in 2025 to USD 3,168.8 million by 2035, reflecting a compound annual growth rate (CAGR) of 6.5%. This expansion is driven by increasing demand for accurate, non-invasive imaging technologies, rising focus on personalized medicine, and growing prevalence of chronic diseases. The market encompasses modalities such as optical imaging, nuclear imaging, PET, SPECT, CT, MRI, micro-ultrasound, photoacoustic imaging, and magnetic particle imaging, alongside reagents including optical imaging reagents, contrast agents, PET tracers, SPECT probes, and nuclear imaging reagents.
North America, Europe, and Asia-Pacific remain the dominant regions, with key players including Pfizer, Johnson & Johnson, Merck, Novartis, Roche, AbbVie, Eli Lilly, AstraZeneca, GSK, and GlaxoSmithKline.
Market size
Growth trajectory through 2035
Preclinical Imaging (In-VIVO) Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Emerging opportunities added
- Hybrid imaging systems The emergence of hybrid modalities combining PET, SPECT, MRI, and CT is creating new avenues for growth and differentiation.
- AI-driven image analysis Integration of artificial intelligence is enhancing the utility of preclinical imaging, enabling faster and more accurate diagnostics.
- Expansion in emerging markets Increasing healthcare investments in Asia-Pacific, Latin America, and the Middle East & Africa are opening new revenue streams.
- Development of targeted imaging agents Advances in molecularly targeted reagents are addressing unmet clinical needs and driving innovation.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $1.69 Bn
- CAGR
- 6.50%
- Expansion
- 1.9×
Market shape
leading region
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High costs of advanced imaging systems
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Capacity announcements, M&A activity, product launches, and funding rounds tracked quarterly in the full report data pack.
- Study window
- 2020–2035
- Base year
- 2025 (actuals)
Report scope
What this report answers
The specific decisions and questions covered in the 159-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Preclinical Imaging (In-VIVO) Market today ($1.69 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
- How do NORTH AMERICA compare on market share, growth rate, and regulatory posture?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Demand for accurate and non-invasive imaging technologies) and top restraints (led by High costs of advanced imaging systems), with quantified CAGR impact?
- What regulatory shifts and recent tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Demand for accurate and non-invasive imaging technologies Rising need for precise imaging tools in early-stage drug development and disease research is accelerating adoption of modalities such as MRI, PET, and optical imaging.
- Focus on personalized medicine Tailored treatments based on individual patient profiles are driving demand for advanced imaging solutions that enable precise diagnostics and monitoring.
- Technological advancements in imaging modalities Improvements in image resolution, sensitivity, and multi-modal capabilities are enhancing research outcomes and supporting market growth.
- Increasing prevalence of chronic diseases Growth in conditions such as cancer, cardiovascular diseases, and neurological disorders is fueling demand for preclinical imaging tools.
- Rising investments in healthcare infrastructure Global investments in healthcare facilities and research institutions are bolstering market expansion.
Restraints
Holding it back
- High costs of advanced imaging systems Systems such as micro-MRI can cost between $1 million and $6 million, limiting accessibility for smaller research institutions.
- Long image acquisition times Extended scan durations may negatively impact animal welfare and research efficiency.
- Regulatory hurdles Approval timelines for novel imaging agents and devices remain extended, delaying market entry for innovative solutions.
- Supply chain challenges Component shortages and logistical constraints continue to impact production and deployment of imaging systems.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Demand for accurate and non-invasive imaging technologies | +2.9% | Global | 2025–2035 |
| Focus on personalized medicine | +1.8% | Global | 2025–2035 |
| Technological advancements in imaging modalities | +1.4% | Global | 2025–2035 |
| Increasing prevalence of chronic diseases | +1.0% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High costs of advanced imaging systems | −1.2% | Global | 2025–2029 |
| Long image acquisition times | −0.8% | Global | 2025–2029 |
| Regulatory hurdles | −0.6% | Global | 2025–2029 |
The preclinical imaging market is segmented by modality and reagent type. Modalities include optical imaging, nuclear imaging, PET, SPECT, CT, MRI, micro-ultrasound, photoacoustic imaging, and magnetic particle imaging. Reagents encompass optical imaging reagents, contrast agents, PET tracers, SPECT probes, and nuclear imaging reagents. These segments reflect the diverse applications and technological advancements driving market growth.
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $1.69 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~39.2% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The market is characterized by the presence of established players such as Pfizer, Johnson & Johnson, Merck, Novartis, Roche, AbbVie, Eli Lilly, AstraZeneca, GSK, and GlaxoSmithKline. These companies leverage extensive R&D capabilities and strategic partnerships to maintain their market positions. The competitive landscape is further shaped by the emergence of niche players focusing on molecularly targeted agents and hybrid imaging systems.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
What is the worth of preclinical imaging (in-vivo) market?
The preclinical imaging (in-vivo) market is expected to grow at 5.85% CAGR from 2023 to 2030. It is expected to reach above USD 1345.93 Million by 2030 from USD 927.43 Million in 2023. -
What is the size of the North America preclinical imaging (in-vivo) industry?
North America held more than 46% of the preclinical imaging (in-vivo) market revenue share in 2022 and will witness expansion in the forecast period. -
What are some of the market's driving forces?
The pharmaceutical and biotechnology industries are constantly seeking new drug candidates and therapies. Preclinical imaging plays a crucial role in evaluating the efficacy, safety, and pharmacokinetics of potential drug candidates. The growing focus on drug discovery and development drives the demand for preclinical imaging systems and services. -
Which are the top companies to hold the market share in preclinical imaging (in-vivo) market?
The preclinical imaging (in-vivo) market key players PerkinElmer Inc., Bruker Corporation, FUJIFILM Holdings Corporation, Mediso Ltd., MILabs B.V., MR Solutions, LI-COR Biosciences, Aspect Imaging, TriFoil Imaging, Miltenyi Biotech GmbH -
What is the leading application of preclinical imaging (in-vivo) market?
The healthcare is major sector where the application of preclinical imaging (in-vivo) has seen more. -
Which is the largest regional market for preclinical imaging (in-vivo) market?
The markets largest share is in the North America region.
The Preclinical Imaging (In-VIVO) Market is projected to reach $3.17 Bn by 2035, up from $1.69 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.